May 13, 2025
Emerging oncology innovator OncoSpherix to showcase breakthrough cancer therapies at global biotech stage in Boston
Atlanta, GA — May 2025 — OncoSpherix, a pre-clinical-stage oncology company advancing novel therapies for unresectable and metastatic cancers, is proud to announce its selection as a finalist for the s 2025 BIO International Convention Start-Up Stadium, taking place June 16–19, 2025 in Boston, Massachusetts.
As one of a select group of innovative biotech companies chosen from a global pool of applicants, OncoSpherix will deliver a live pitch presentation on Tuesday, June 17 at 3:48 PM ET during the Start-Up Stadium event. The presentation will be delivered by Dr. Margaret K. Offermann, CEO of OncoSpherix, and will highlight the company’s proprietary therapeutic platform and development pipeline targeting advanced cancers.
“We are honored to be recognized as a finalist and to join the BIO Start-Up Stadium — a premier global stage for emerging biotech innovators,” said Dr. Offermann. “This opportunity provides tremendous visibility and a gateway to new strategic partnerships, investors, and collaborators who share our mission of transforming outcomes for patients facing serious oncologic diseases.”
Finalists in the BIO Start-Up Stadium gain access to BIO’s Partnering™ platform, enabling high-value connections with potential investors, biopharma partners, and service providers. OncoSpherix will leverage this platform to explore new collaborations that support its ongoing Series A fundraising and clinical development efforts.
For more details on the event, visit: https://convention.bio.org/program/start-up-stadium
About OncoSpherix:
OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supplies, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candidate has been shown in mouse models to reduce primary tumor growth, inhibit metastasis, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). OncoSpherix intends to advance its lead candidate in one or more of these indications.
Company Contact:
Allan Valmonte
VP of Business Operations
Source: OncoSpherix, Inc.